PHARMOS's total assets reached CZK 3,460 mil at the end of 2019, down 0.661% compared to the previous year.
Current assets amounted to CZK 3,099 mil, or 89.6% of total assets while cash stood at CZK 51.9 mil at the end of 2019.
By contrast, total debt reached CZK 1,473 mil at the year-end, or 42.6% of total assets, while the firm's equity amounted to CZK 653 mil. As a result, net debt stood at CZK 1,245 mil at the end of 2019 and accounted for 191% of equity.
Net debt against equity is up 191 pp from five years ago (). The ratio against EBITDA increased from x seen in 2014 to 21.7x.
The company’s cost of funding amounted to 2.83% in 2019, up 0.393 pp compared to the average over the last 5 years.
You can see all the company’s data at PHARMOS profile, or you can download a report on the company in the report section.
Helgi Library 
